Browsing Tag
Inozyme Pharma
3 posts
BioMarin’s BMN 401 setback raises regulatory questions after ENPP1 deficiency trial meets only one endpoint
BioMarin moved the biomarker, not the rickets score. BMN 401 now tests how much regulators will accept in ultra-rare disease trials.
Inozyme Pharma presents positive interim data on INZ-701 at CHOP Cardiology 2025
Inozyme Pharma Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases affecting bone…
Inozyme Pharma acquires Alexion’s ENPP1 gene deficiency program assets
Inozyme Pharma said that it has acquired Alexion Pharmaceuticals’ intellectual property and assets focused on ENPP1 gene deficiencies…